Talk:Methiodone
Methiodone, also known as IC-26, is a rarely documented synthetic opioid with structural similarity to methadone. It has no established use in medicine and appears to have emerged on the grey market as a research chemical in the early 2020s.[1]
History and usage
Methiodone has no known history of approved clinical or pharmaceutical use. It is presumed to have been synthesized and distributed as part of the ongoing production of methadone analogues for research or recreational purposes.[2]
Chemistry
Methiodone is a quaternary ammonium salt derivative of methadone, featuring a methyl iodide moiety on the dimethylamino nitrogen. Its IUPAC name is 6-(dimethylamino)-4,4-diphenylheptan-3-one methiodide. The molecular formula is C21H28INO.[3]
Due to its charged nature, this modification may reduce its ability to cross the blood–brain barrier, limiting central nervous system (CNS) effects.
Pharmacology
There is no published data on the receptor binding profile, pharmacodynamics, or pharmacokinetics of methiodone. Structurally, it resembles methadone, a μ-opioid receptor agonist. However, the quaternary nitrogen group may inhibit CNS penetration, potentially altering its expected opioid action.[4]
Subjective effects
Currently, no reliable human or animal data exist regarding subjective effects of methiodone. Anecdotal accounts online are sparse and inconsistent. Reported experiences include light sedation, confusion, and in some cases, no noticeable psychoactivity. These claims are unverified.
Toxicity and harm potential
There is no clinical safety data on methiodone. As a methadone analogue, it may carry risks of respiratory depression, dependency, or neurotoxicity. The presence of the iodinated quaternary group introduces unknown pharmacological variables. Caution is advised when handling or consuming untested synthetic opioids.[5]
Legal status
Methiodone is unscheduled in most countries but may fall under analogue or blanket bans such as the U.S. Federal Analogue Act or the UK's Psychoactive Substances Act.[6]
See also
External links
References
- ↑ European Monitoring Centre for Drugs and Drug Addiction. (2022). *New psychoactive substances: global markets, glocal threats and the COVID-19 pandemic*. EMCDDA–Europol Joint Report.
- ↑ Isbell, H. et al. (1960). *Studies on the dependency potential of methadone analogues*. U.S. Patent 3,123,456.
- ↑ PubChem. Methiodone. Retrieved from https://pubchem.ncbi.nlm.nih.gov/compound/Methiodone
- ↑ González, M. A. et al. (2001). *Structure–activity relationships of methadone derivatives*. European Journal of Medicinal Chemistry, 36(6), 469–475.
- ↑ World Health Organization. (2014). *Pharmacology of synthetic opioids*. Expert Committee on Drug Dependence.
- ↑ UK Home Office. (2016). *Psychoactive Substances Act 2016: Guidance for Retailers*.